Bioiberica to Unveil Clinical Findings on Collavant N2 for Joint Health

04.15.24

The company’s native type II collagen was linked to significant improvements in self-reported joint discomfort.

Booth F142
 
Global life science company Bioiberica will be showcasing new clinical findings on its native type II collagen ingredient, Collavant n2, at Vitafoods Europe, just after the study’s official presentation at the Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis.
 
Bioiberica’s experts will discuss the results, which indicate that supplementing with 40 mg daily of Collavant n2 may alleviate joint discomfort after exercise.
 
The findings, conducted by Bioiberica in collaboration with the Poal Institute of Rheumatology in Barcelona, were gathered over a six month period in which participants either took the supplement or a matching placebo, and were assessed at 60, 90, 120, and 180 days using Knee Injury and Osteoarthritis Outcome Score (KOOS) assessments.
 
The outcomes revealed a significant reduction in joint discomfort on day 120 and an improvement in quality of life from day 90 versus baseline in the Collavant n2 group. In subjects with basal activity-related discomfort, statistically significant improvements versus placebo were detected at day 180 for both joint discomfort and quality of life.
 
Collavant n2 also was associated with a faster recovery time from discomfort after exercise during the trial, which reached clinical significance at day 180.
 
“This marks the first exploration of Collavant n2’s effects in healthy individuals, and not just those with joint health conditions. In my view, native type II collagen is a pro-health nutritional solution and this research confirms my belief that it could be beneficial for ‘everyday consumers’ leading active lifestyles or regularly engaged in sports; a demographic that continues to grow,” said Ingrid Möller, PhD, rheumatologist at Poal Institute of Rheumatology.
 
“This research could be a game changer in the field of nutrition innovation,” said Daniel Martínez-Puig, head of R&D in human and animal health at Bioiberica, and co-investigator. “Not only were the initial findings promising, but the positive effects of Collavant n2 were observed after just three months. This suggests the ingredient could therefore contribute to overall satisfaction and compliance with products featuring it.”
 
Martínez-Puig will present the study’s key findings at the New Ingredients Theater on May 15 at 3:30 p.m. CET.
 
In addition to new research on Collavant n2, the company will also be sharing the latest developments surrounding its other ingredients, such as Dermial for skin health, Mobilee for muscle and joint health, and DAOgest for digestive health.
 
The company will also discuss its contributions to sustainability in the life sciences sector, its environmental, social, and governance (ESG) framework, and other sustainability initiatives such as plans to achieve climate neutrality by 2050 and commitments to two sustainable development goals (SDGs).
 
The company will also discuss efforts to support One Health, a multi-sector initiative recognizing the interactions and mutual dependencies between human, animal, and environmental health.